DCP-001 not checked

Mendus

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia (AML), Leukemic Dendritic Cell Vaccination
Main trialPhase 2
“Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD”In the company’s words, NCT03697707 on ClinicalTrials.gov

Other drugs for Acute Myeloid Leukemia in Remission

All 8 drugs for Acute Myeloid Leukemia in Remission

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Unknown Mar 2023 Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
Phase 1/2Completed Feb 2013 Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow DCP-001

Following is part of Solo: you see every change to DCP-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in